



Analyst: Neetika Gupta

# The Company for Cooperative Insurance - 4Q23 Result Review

Recommendation:	Accumulate	Target Price (SAR):	UR
Previous Reco. & Date:	TP: SAR 133.21per s	hare; Accumulate on 16-November-2023 Upside / (Downside):	-
		Date: 11-03	3 <b>-202</b> 4
Bloomberg Ticker	TAWUNIYA AB		
Current Market Price (SAR)	149.6	4,000 7	- 180
52wk High / Low (SAR)	163.2/77.917	3,500 -	160
12m Average Vol. (000)	356.8	3,000	140
Mkt. Cap. (USD/SAR mn)	6059/22440	2,500	120
Shares Outstanding (mn)	150.0	2,000	100
Free Float (%)	74%	1,500	- 80 - 60
3m Avg Daily Turnover (000)	38,300.0	1,000 -	40
6m Avg Daily Turnover (000)	41,300.0	500 + 1   11   12   13   14   15   17   18   18   19   19   19   19   19   19	- 20
P/E'24e (x)	23.3x	O THE WINDOWS TO PRODUCE THE PROPERTY OF THE P	4 0
P/BV'24e (x)	6.3x	Mar-23 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Ma	ar-24
Dividend Yield '24e (%)	3.9%		
Price Perf. (1m/3m) (%)	12%/15%	Volume, '000 (LHS) — TAWUNIYA AB , OAR (RHS)	

#### Insurance revenue improve 29% YoY in 4Q23, in-line with Bloomberg consensus but ahead of U-Capital estimate

Tawuniya posted an insurance revenue of SAR 4,200mn (29% YoY and 6% QoQ) in 4Q23, in-line with Bloomberg consensus of SAR 4,254mn but ahead of U-Capital estimate of SAR 3,812mn. For FY23, Insurance revenue stood at SAR 15,265mn reflecting a 34% YoY growth compared to FY22. This growth was primarily driven by a 28.6% growth in GWP due to the strong performance of the main business lines (Health, Motor, and General insurance).

#### Insurance Service results grows significantly QoQ in 4Q23

Insurance service results for Tawuniya for 4Q23 stood at SAR 430mn (-33% YoY and 194% QoQ) largely in line with U-Capital estimate of SAR 466mn. This significant QoQ growth is due to reduction in service expenses for 4Q23 as compared to 3Q23. For FY23, Insurance service results stood at SAR 1,198mn reflecting a 30% YoY growth driven by an increase of insurance revenues supported by a better management of claims leading to reduction in incurred claims.

#### Net income decreases significantly in 4Q23, below Bloomberg consensus

The company's net income for the quarter stood at SAR 90mm (-62% YoY and -56% QoQ), below Bloomberg consensus of SAR 195mm. Tawuniya has restated its financials in accordance with IFRS 9 & 17 standards, leading to significant changes in the presentation of financial results, including restating comparative periods under the new standards and the lack of availability of restated financials for 4Q22 contributed to the deviation. For FY23, net income amounted to SAR 616mm, reflecting a growth of 104% YoY. This growth can be attributed to the improvement in insurance service results, along with increased investment income driven by higher interest rates and consistent fixed income returns throughout the FY23.

#### **Target Price Under Review**

Tawuniya achieved impressive FY23 results, exhibiting a remarkable 104% YoY net income growth. We assigned Accumulate rating to Tawuniya with a target price of SAR 133.24 on 16th November. Since then, the stock has appreciated by 37%, ahead of our target price of SAR 133.24. We maintain **Accumulate** rating on the stock and put the target price Under Review.

#### **Valuation**

Tawuniya is trading at 2024e P/E of 23.3x compared to the historical average 1-year forward P/E of 25.2x. Additionally, the stock is valued at P/BV multiple of 6.3x, based on the FY24 estimate, compared to the historical average of 4.5x.

Income Statement												
(SAR mn)	4Q22	1Q23	2Q23	3Q23	4Q23	4Q23e	YoY (%)	QoQ (%)	Var (%)	FY22	FY23	YoY (%)
Insurance Revenue	3,260	3,407	3,697	3,961	4,200	3,812	29%	6%	10%	11,408	15,265	34%
Insurance service results	639	162	460	146	430	466	-33%	194%	-8%	923	1,198	30%
Net Investment Income	111	103	103	113	117	108	5%	4%	8%	372	436	17%
Net Profit (Loss)	233	74	246	206	90	364	-62%	-56%	-75%	302	616	104%
Balance Sheet												
(SAR mn)	4Q22	1Q23	2Q23	3Q23	4Q23	4Q23e	YoY (%)	QoQ (%)	Var (%)	FY22	FY23	YoY (%)
Shareholders' Equity	3,126	3,228	3,348	3,304	3,615	3,444	16%	9%	5%	3,126	3,615	16%
Key Ratios												
	4Q22	1Q23	2Q23	3Q23	4Q23	4Q23e	YoY (%)	QoQ (%)	Var (%)	FY22	FY23	YoY (%)
Insurance service results margins	19.6%	4.8%	12.4%	3.7%	10.2%	12.2%				8.1%	7.8%	
Net Profit Margin	7.2%	2.2%	6.6%	5.2%	2.1%	9.6%				2.6%	4.0%	
ROE	29.9%	9.2%	29.4%	25.0%	9.9%	42.3%				9.7%	17.1%	

Source: Financials, Tadawul Disclosure, Bloomberg, U Capital Research

For our earlier report, please click here.





# **Investment Research**

Ubhar-Research@u-capital.net

# **Head of Research**

## Neetika Gupta

+968 2494 9036

neetika@u-capital.net

# **Research Team**

### Ahlam Al-Harthi

+968 2494 9024

ahlam.harthi@u-capital.net

### **Said Ghawas**

+968 2494 9034

said.ghawas@u-capital.net

### Amira Al Alawi

+968 2494 9112

= amira.alalawi@u-capital.net

# **Head of Brokerage**

### Talal Al Balushi

+968 2494 9051

talal@u-capital.net

Visit us at: www.u-capital.net







### Recommendation

BUY	Greater than 20%
ACCUMULATE	Between +10% and +20%
HOLD	Between +10% and -10%
REDUCE	Between -10% and -20%
SELL	Lower than -20%



### **Ubhar Capital SAOC (U Capital)**

Website: www.u-capital.net
PO Box 1137
PC 111, Sultanate of Oman
Tel: +968 2494 9000
Fax: +968 2494 9099
Email: research@u-capital.net

**Disclaimer:** This report has been prepared by Ubhar Capital (U Capital) Research, and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report, and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.